S. Heintzman

发表

Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines

Andrea D Matlock, J. Krakauer, K. Sachs, 2020, Nature Neuroscience.

CuATSM effectively ameliorates ALS patient astrocyte‐mediated motor neuron toxicity in human in vitro models of amyotrophic lateral sclerosis

Cassandra N. Dennys, M. Franco, K. Meyer, 2022, Glia.

Safety, Tolerability, and Effect of Nusinersen Treatment in Ambulatory Adults With 5q-SMA

W. Arnold, B. Elsheikh, Songzhu Zhao, 2021, Frontiers in Neurology.

Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy

W. Arnold, B. Elsheikh, Songzhu Zhao, 2021, Frontiers in Neurology.

Psychometric evaluation of modified spinal muscular atrophy functional rating scale (SMAFRS) in adult patients using Rasch analysis

W. Arnold, J. Montes, A. Bartlett, 2023, Muscle & nerve.

Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen.

W. Arnold, B. Elsheikh, K. Rajneesh, 2021, Journal of neuromuscular diseases.

Health-related quality-of-life scores, spine-related symptoms, and reoperations in young adults 7 to 17 years after surgical treatment of adolescent idiopathic scoliosis.

L. Carreon, C. Crawford, Chelsea E. Canan, 2015, American journal of orthopedics.

Identifying patterns in amyotrophic lateral sclerosis progression from sparse longitudinal data

Kristen A. Severson, Andrea D Matlock, J. Krakauer, 2022, Nature Computational Science.

Effect of Treatment of Mild Gestational Diabetes on Long-Term Maternal Outcomes

M. Rice, G. Saade, E. Thom, 2019, American Journal of Perinatology.

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

E. Nordh, Yi-Chung Lee, R. Sommerville, 2020, Lancet Neurology.

Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study

Adam L. Comer, Robert G. Miller, S. Demeret, 2023, The Lancet Neurology.

EphA4 targeting agents protect motor neurons from cell death induced by amyotrophic lateral sclerosis -astrocytes

C. Baggio, M. Pellecchia, Cassandra N. Dennys, 2022, iScience.

Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen

W. Arnold, B. Elsheikh, Songzhu Zhao, 2021, BMJ Neurology Open.

Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial

L. Greensmith, J. Albayda, J. Statland, 2023, The Lancet Neurology.

Differential impact on motor unit characteristics across severities of adult spinal muscular atrophy

K. Rajneesh, Kristina M Kelly, J. Reynolds, 2023, Annals of clinical and translational neurology.